{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:02:52Z","timestamp":1791406972008,"version":"4.3.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,8]]},"DOI":"10.7759\/cureus.77159","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T02:37:25Z","timestamp":1736390245000},"source":"Crossref","is-referenced-by-count":1,"title":["Breaking Barriers: Tackling Racial and Socioeconomic Disparities in the Prescription of Life-Saving SGLT2 Inhibitors for Proteinuria"],"prefix":"10.7759","author":[{"given":"Shay","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samrawit W","family":"Zinabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Edmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Lyles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pempeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Micheal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.79a.11109","article-title":"Hypertensive chronic kidney disease in African Americans: strategies for improving care","volume":"79","author":"Martins D","year":"2012","unstructured":"Martins D, Agodoa L, Norris KC. Hypertensive chronic kidney disease in African Americans: strategies for improving care. Cleve Clin J Med. 2012, 79:726-34. 10.3949\/ccjm.79a.11109","journal-title":"Cleve Clin J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-020-02361-w","article-title":"Glucose transporters in the kidney in health and disease","volume":"472","author":"Vallon V","year":"2020","unstructured":"Vallon V. Glucose transporters in the kidney in health and disease. Pflugers Arch. 2020, 472:1345-70. 10.1007\/s00424-020-02361-w","journal-title":"Pflugers Arch"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau K","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZ. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022, 7:1463-76. 10.1016\/j.ekir.2022.04.094","journal-title":"Kidney Int Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa JI","year":"2021","unstructured":"Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review. Front Med (Lausanne). 2021, 8:777861. 10.3389\/fmed.2021.777861","journal-title":"Front Med (Lausanne)"},{"key":"ref5","article-title":"Renal physiology","author":"Bailey MA","year":"2024","unstructured":"Bailey MA, Unwin RJ. Renal physiology. Comprehensive Clinical Nephrology, 7th ed. Floege J, Johnson RJ, Feehally J (ed): Elsevier Health Sciences, Philadelphia, PA; 2024. 13-23."},{"key":"ref6","article-title":"Physiology, renal blood flow and filtration","author":"Dalal R","year":"2023","unstructured":"Dalal R, Bruss ZS, Sehdev JS. Physiology, renal blood flow and filtration. StatPearls [Internet]. StatPearls Publising, Treasure Island (FL); 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.872918","article-title":"Update on pathogenesis of glomerular hyperfiltration in early diabetic kidney disease","volume":"13","author":"Yang Y","year":"2022","unstructured":"Yang Y, Xu G. Update on pathogenesis of glomerular hyperfiltration in early diabetic kidney disease. Front Endocrinol (Lausanne). 2022, 13:872918. 10.3389\/fendo.2022.872918","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of diabetes medications used by adults with commercial insurance vs Medicare Advantage, 2016 to 2019","volume":"4","author":"McCoy RG","year":"2021","unstructured":"McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND. Comparison of diabetes medications used by adults with commercial insurance vs Medicare Advantage, 2016 to 2019. JAMA Netw Open. 2021, 4:e2035792. 10.1001\/jamanetworkopen.2020.35792","journal-title":"JAMA Netw Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly LA","year":"2021","unstructured":"Eberly LA, Yang L, Eneanya ND, et al.. Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw Open. 2021, 4:e216139. 10.1001\/jamanetworkopen.2021.6139","journal-title":"JAMA Netw Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13885","article-title":"Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health Administration system","volume":"328","author":"Lamprea-Montealegre JA","year":"2022","unstructured":"Lamprea-Montealegre JA, Madden E, Tummalapalli SL, et al.. Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health Administration system. JAMA. 2022, 328:861-71. 10.1001\/jama.2022.13885","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.11.017","article-title":"Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD","volume":"82","author":"Gregg LP","year":"2023","unstructured":"Gregg LP, Ramsey DJ, Akeroyd JM, Jafry SA, Matheny ME, Virani SS, Navaneethan SD. Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD. Am J Kidney Dis. 2023, 82:53-62.e1. 10.1053\/j.ajkd.2022.11.017","journal-title":"Am J Kidney Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.deman.2023.100184","article-title":"Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk","volume":"13","author":"Scheen AJ","year":"2024","unstructured":"Scheen AJ.  Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk. Diabetes Epidemiol Manag. 2024, 13:100184. 10.1016\/j.deman.2023.100184","journal-title":"Diabetes Epidemiol Manag"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2017.0925","article-title":"The effect of Medicaid on medication use among poor adults: evidence from Oregon","volume":"36","author":"Baicker K","year":"2017","unstructured":"Baicker K, Allen HL, Wright BJ, Finkelstein AN. The effect of Medicaid on medication use among poor adults: evidence from Oregon. Health Aff (Millwood). 2017, 36:2110-4. 10.1377\/hlthaff.2017.0925","journal-title":"Health Aff (Millwood)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01154-w","article-title":"Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes","volume":"19","author":"Schernthaner G","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS, et al.. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020, 19:185. 10.1186\/s12933-020-01154-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100477","article-title":"Call to action: understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists","volume":"13","author":"Khedagi A","year":"2023","unstructured":"Khedagi A, Hoke C, Kelsey M, et al.. Call to action: understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists. Am J Prev Cardiol. 2023, 13:100477. 10.1016\/j.ajpc.2023.100477","journal-title":"Am J Prev Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4205","article-title":"Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types","volume":"2","author":"Tummalapalli SL","year":"2021","unstructured":"Tummalapalli SL, Montealegre JL, Warnock N, Green M, Ibrahim SA, Estrella MM. Coverage, formulary restrictions, and affordability of sodium-glucose cotransporter 2 inhibitors by US insurance plan types. JAMA Health Forum. 2021, 2:e214205. 10.1001\/jamahealthforum.2021.4205","journal-title":"JAMA Health Forum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/308832-breaking-barriers-tackling-racial-and-socioeconomic-disparities-in-the-prescription-of-life-saving-sglt2-inhibitors-for-proteinuria","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T02:37:27Z","timestamp":1736390247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/308832-breaking-barriers-tackling-racial-and-socioeconomic-disparities-in-the-prescription-of-life-saving-sglt2-inhibitors-for-proteinuria"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.77159","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}